SCHEDULE 13G: Aptevo Therapeutics: Intracoastal Capital and Affiliates Report 0% Beneficial Ownership After Initial Disclosure

A Schedule 13G filing reveals that Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC currently hold 0% beneficial ownership in Aptevo Therapeutics Inc., following an initial potential ownership of 8.3% tied to a Securities Purchase Agreement.

Summary

• The filing is a Schedule 13G for Aptevo Therapeutics Inc. common stock, par value $0.001 per share, with CUSIP Number 03835L405.
• The reporting persons are Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC.
• Immediately following the execution of a Securities Purchase Agreement (SPA) with Aptevo Therapeutics Inc. on April 21, 2025, the reporting persons were deemed to have beneficial ownership of 290,000 shares of Common Stock, representing approximately 8.3% of the Common Stock.
• This 8.3% calculation was based on 3,223,214 shares of Common Stock outstanding as of April 17, 2025, plus the 290,000 shares to be issued at the SPA closing.
• The initial deemed beneficial ownership excluded 310,000 shares of Common Stock issuable upon exercise of the 'Intracoastal Warrant' because it is not exercisable until stockholder approval and contains a blocker provision limiting beneficial ownership to 4.99%.
• As of the close of business on April 25, 2025, the reporting persons are deemed to have beneficial ownership of 0 shares of Common Stock.
• The 310,000 shares from the Intracoastal Warrant remain excluded from current beneficial ownership due to the same exercisability conditions (stockholder approval and 4.99% blocker).
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 3

Explanation: The sentiment is slightly negative because the reported beneficial ownership for the reporting persons reverted to 0% shortly after an initial potential 8.3% stake, and a significant portion of their potential investment (warrant shares) remains unexercisable due to a blocker and approval requirements.

Positives

• The reporting persons explicitly state that their holdings are not for the purpose of changing or influencing control of Aptevo Therapeutics, indicating a passive investment stance.

Negatives

• The reporting persons' beneficial ownership has reverted to 0% as of April 25, 2025, after an initial potential ownership of 8.3%, which might indicate a change in their investment position or the non-completion of the initial share issuance.
• A significant portion of potential shares (310,000 from the Intracoastal Warrant) are not currently exercisable due to a 4.99% blocker provision and the requirement for stockholder approval, limiting immediate upside for the warrant holder.

Risks

• The non-exercisability of the Intracoastal Warrant due to a 4.99% blocker and the need for stockholder approval introduces uncertainty regarding the full realization of the investment for the warrant holder.
• The shift from a potential 8.3% beneficial ownership to 0% could imply a transaction did not close as initially contemplated or that the shares were disposed of, which might raise questions about the underlying deal or the company's stock.

Future Outlook

The document does not provide forward-looking statements or guidance from the issuer, focusing solely on the reporting persons' beneficial ownership status.

Industry Context

This Schedule 13G filing is a standard disclosure for passive investors crossing certain ownership thresholds. It does not provide specific industry context beyond the fact that Aptevo Therapeutics Inc. is a publicly traded company subject to SEC reporting requirements. The change in reported beneficial ownership from a potential 8.3% to 0% for the reporting persons could be a result of the specific terms of the Securities Purchase Agreement or subsequent market activities, but the filing itself does not elaborate on broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The change in beneficial ownership from a potential 8.3% to 0% for these specific investors might be interpreted differently by the market. The existence of a warrant requiring shareholder approval for exercise indicates future dilution potential if approved and exercised.

Next Steps

• Stockholder approval is required for the issuance of shares upon exercise of the Intracoastal Warrant.

Key Dates

Keywords

Aptevo Therapeutics Inc., Schedule 13G, Beneficial Ownership, Intracoastal Capital LLC, Mitchell P. Kopin, Daniel B. Asher, Common Stock, SEC Filing, Investment, Warrant, Shareholder Disclosure